105 related articles for article (PubMed ID: 7864230)
1. TxA2 receptor activation elicits organ-specific increases in microvascular permeability in the rat.
Bertolino F; Valentin JP; Maffre M; Bessac AM; John GW
Am J Physiol; 1995 Feb; 268(2 Pt 2):R366-74. PubMed ID: 7864230
[TBL] [Abstract][Full Text] [Related]
2. Nitric oxide regulation of TP receptor-mediated pulmonary vasoconstriction in the anesthetized, open-chest rat.
Valentin JP; Bessac AM; Maffre M; John GW
Eur J Pharmacol; 1996 Dec; 317(2-3):335-42. PubMed ID: 8997619
[TBL] [Abstract][Full Text] [Related]
3. Losartan prevents thromboxane A2/prostanoid (TP) receptor mediated increase in microvascular permeability in the rat.
Valentin JP; Jover B; Maffre M; Bertolino F; Bessac AM; John GW
Am J Hypertens; 1997 Sep; 10(9 Pt 1):1058-63. PubMed ID: 9324114
[TBL] [Abstract][Full Text] [Related]
4. Prevention of thromboxane A2 receptor-mediated pulmonary hypertension by a nonpeptide angiotensin II type 1 receptor antagonist.
Bertolino F; Valentin JP; Maffre M; Jover B; Bessac AM; John GW
J Pharmacol Exp Ther; 1994 Feb; 268(2):747-52. PubMed ID: 8113986
[TBL] [Abstract][Full Text] [Related]
5. Intrinsic activity of the non-prostanoid thromboxane A2 receptor antagonist, daltroban (BM 13,505), in human platelets in vitro and in the rat vasculature in vivo.
Bertolino F; Valentin JP; Maffre M; Grelac F; Bessac AM; Maclouf J; Delhon A; Lévy-Toledano S; Patoiseau JF; Colpaert FC
Br J Pharmacol; 1995 May; 115(1):210-6. PubMed ID: 7647979
[TBL] [Abstract][Full Text] [Related]
6. Dose-dependent mediation of leukotriene D4-induced airway microvascular leakage and bronchoconstriction in the guinea pig.
Bochnowicz S; Underwood DC
Prostaglandins Leukot Essent Fatty Acids; 1995 Jun; 52(6):403-11. PubMed ID: 7644563
[TBL] [Abstract][Full Text] [Related]
7. Influence of SQ 30741 on thromboxane receptor-mediated responses in the feline pulmonary vascular bed.
McMahon TJ; Hood JS; Nossaman BD; Ibrahim IN; Feng CJ; Kadowitz PJ
J Appl Physiol (1985); 1991 Nov; 71(5):2012-8. PubMed ID: 1837015
[TBL] [Abstract][Full Text] [Related]
8. [Losartan prevents pulmonary hypertension induced by a thromboxane A2 analog].
Bertolino F; Valentin JP; Maffre M; Jover B; Bessac AM; John GW
Arch Mal Coeur Vaiss; 1994 Aug; 87(8):971-4. PubMed ID: 7755474
[TBL] [Abstract][Full Text] [Related]
9. Thromboxane A2-mimetics are potent microvascular permeability factors in the conjunctiva.
Woodward DF; Nieves AL; Williams LS
J Pharmacol Exp Ther; 1990 Oct; 255(1):23-7. PubMed ID: 2213558
[TBL] [Abstract][Full Text] [Related]
10. Prostaglandin B2-induced pulmonary hypertension is mediated by TxA2/PGH2 receptor stimulation.
Liu F; Orr JA; Wu JY
Am J Physiol; 1994 Nov; 267(5 Pt 1):L602-8. PubMed ID: 7977770
[TBL] [Abstract][Full Text] [Related]
11. AGN 191976: a novel thromboxane A2-mimetic with ocular hypotensive properties.
Krauss AH; Woodward DF; Chen J; Gibson LL; Lai RK; Protzman CE; Shan T; Williams LS; Gac TS; Burk RM
J Ocul Pharmacol Ther; 1995; 11(3):203-12. PubMed ID: 8590251
[TBL] [Abstract][Full Text] [Related]
12. Diaphragmatic failure during group B streptococcal sepsis in piglets: the role of thromboxane A2.
Murphy TD; Gibson RL; Standaert TA; Woodrum DE
J Appl Physiol (1985); 1995 Feb; 78(2):491-8. PubMed ID: 7759417
[TBL] [Abstract][Full Text] [Related]
13. Renal vasoconstriction with U-46,619; role of arachidonate metabolites.
Wilcox CS; Folger WH; Welch WJ
J Am Soc Nephrol; 1994 Oct; 5(4):1120-4. PubMed ID: 7849252
[TBL] [Abstract][Full Text] [Related]
14. Influence of thromboxane A2 receptor antagonism on pulmonary vasoconstrictor responses.
Bradley LM; Stambouly JJ; Czaja JF; Goldstein RE
Pediatr Res; 1989 Sep; 26(3):175-9. PubMed ID: 2587116
[TBL] [Abstract][Full Text] [Related]
15. Central thromboxane receptors: mRNA expression and mediation of pressor responses.
Gao H; Peng B; Welch WJ; Wilcox CS
Am J Physiol; 1997 May; 272(5 Pt 2):R1493-500. PubMed ID: 9176341
[TBL] [Abstract][Full Text] [Related]
16. A thromboxane mimetic, U-46619, produces plasma exudation in airways of the guinea pig.
Lötvall J; Elwood W; Tokuyama K; Sakamoto T; Barnes PJ; Chung KF
J Appl Physiol (1985); 1992 Jun; 72(6):2415-9. PubMed ID: 1385805
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological evidence for thromboxane receptor heterogeneity--implications for the eye.
Krauss AH; Woodward DF; Burk RM; Gac TS; Gibson LL; Protzman CE; Abbass F; Marshall K; Senior J
J Ocul Pharmacol Ther; 1997 Aug; 13(4):303-12. PubMed ID: 9261766
[TBL] [Abstract][Full Text] [Related]
18. Antiaggregant and antivasospastic properties of the new thromboxane A2 receptor antagonist sodium 4-[[1-[[[(4-chlorophenyl)sulfonyl]amino]methyl]cyclopentyl] methyl]benzeneacetate.
Lardy C; Rousselot C; Chavernac G; Depin JC; Guerrier D
Arzneimittelforschung; 1994 Nov; 44(11):1196-202. PubMed ID: 7848331
[TBL] [Abstract][Full Text] [Related]
19. Gestational resistance to the pulmonary vasoconstrictor effect of the TxA2 mimetic U-46619: possible mechanism.
Losonczy G; Brown G; Mucha I; Klocke R; Muller V; Merkely B; Tornoci L; Rosivall L; Venuto R
Am J Physiol; 1997 Jun; 272(6 Pt 2):R1734-9. PubMed ID: 9227584
[TBL] [Abstract][Full Text] [Related]
20. Activation of the central cholinergic system mediates the reversal of hypotension by centrally administrated U-46619, a thromboxane A2 analog, in hemorrhaged rats.
Yalcin M; Cavun S; Yilmaz MS; Savci V
Brain Res; 2006 Nov; 1118(1):43-51. PubMed ID: 16962568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
